These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9665149)

  • 41. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
    Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
    Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
    Benko G; Spajić B; Krušlin B; Tomas D
    Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma.
    Cote RJ; Shi Y; Groshen S; Feng AC; Cordon-Cardo C; Skinner D; Lieskovosky G
    J Natl Cancer Inst; 1998 Jun; 90(12):916-20. PubMed ID: 9637141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
    J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy.
    Arslan B; Onuk Ö; Hazar İ; Aydın M; Çilesiz NC; Eroglu A; Nuhoglu B
    Tumori; 2017 Mar; 103(2):204-208. PubMed ID: 27470607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of human bone sialoprotein in normal and pathological tissues using a monoclonal antibody (BSP 1.2 mab).
    Cogan G; Bansal AK; Ibrahim S; Zhu B; Goldberg HA; Ganss B; Cheifetz S; Armbruster FP; Sodek J
    Connect Tissue Res; 2004; 45(1):60-71. PubMed ID: 15203941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone sialoprotein stimulates focal adhesion-related signaling pathways: role in migration and survival of breast and prostate cancer cells.
    Gordon JA; Sodek J; Hunter GK; Goldberg HA
    J Cell Biochem; 2009 Aug; 107(6):1118-28. PubMed ID: 19492334
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development.
    Bellahcene A; Kroll M; Liebens F; Castronovo V
    J Bone Miner Res; 1996 May; 11(5):665-70. PubMed ID: 9157781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy.
    Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
    Prostate; 2012 Feb; 72(3):270-9. PubMed ID: 21630293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PSA at postoperative three months can predict biochemical recurrence in patients with pathological T3 prostate cancer following radical prostatectomy.
    Inagaki T; Kohjimoto Y; Nishizawa S; Kuramoto T; Nanpo Y; Fujii R; Matsumura N; Shintani Y; Uekado Y; Hara I
    Int J Urol; 2009 Dec; 16(12):941-6. PubMed ID: 19832922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Residual prostatic tumour in the surgical bed following radical prostatectomy in organ-confined prostate cancer: possible prognostic significance.
    Valotto C; Falconieri G; Pizzolitto S; Cerruto MA; Brondani G; De Gobbi A; Zattoni F
    Arch Ital Urol Androl; 2011 Jun; 83(2):78-82. PubMed ID: 21826879
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
    Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
    Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [